Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease : a randomized, controlled clinical trial
Segarra, Sergi
Martínez-Subiela, Silvia
Cerdà-Cuéllar, Marta (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal)
Martínez-Puig, Daniel
Muñoz-Prieto, Alberto
Rodríguez Franco, Fernando (Universidad Complutense de Madrid. Departamento de Medicina y Cirugía Animal)
Rodríguez-Bertos, Antonio (Universidad Complutense de Madrid)
Allenspach, Karin
Velasco, Alfonso
Cerón, José Joaquín (Universidad de Murcia. Departamento de Patología Animal)

Date:	2016
Abstract:	Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress. Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0. 05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0. 001). After treatment, a significant decrease (1. 53-fold; p < 0. 01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0. 05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0. 01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0. 05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group. The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Chronic enteropathy ; Dog ; Glycosaminoglycan ; Resistant starch ; β-glucans ; Oxidative stress ; CIBDAI
Published in:	BMC veterinary research, Vol. 12 (march 2016) , ISSN 1746-6148

DOI: 10.1186/s12917-016-0676-x
PMID: 26965834

9 p, 1.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Centre de Recerca en Sanitat Animal (CReSA-IRTA)
Articles > Research articles
Articles > Published articles